Cargando…
Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease
Plasma free fatty acid (FFA) concentration is elevated in obesity, insulin resistance (IR), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), and related comorbidities such as cardiovascular disease (CVD). Furthermore, experimentally manipulating plasma FFA in the laboratory setting...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402049/ https://www.ncbi.nlm.nih.gov/pubmed/34444750 http://dx.doi.org/10.3390/nu13082590 |
_version_ | 1783745695538216960 |
---|---|
author | Henderson, Gregory C. |
author_facet | Henderson, Gregory C. |
author_sort | Henderson, Gregory C. |
collection | PubMed |
description | Plasma free fatty acid (FFA) concentration is elevated in obesity, insulin resistance (IR), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), and related comorbidities such as cardiovascular disease (CVD). Furthermore, experimentally manipulating plasma FFA in the laboratory setting modulates metabolic markers of these disease processes. In this article, evidence is presented indicating that plasma FFA is a disease risk factor. Elevations of plasma FFA can promote ectopic lipid deposition, IR, as well as vascular and cardiac dysfunction. Typically, elevated plasma FFA results from accelerated adipose tissue lipolysis, caused by a high adipose tissue mass, adrenal hormones, or other physiological stressors. Reducing an individual’s postabsorptive and postprandial plasma FFA concentration is expected to improve health. Lifestyle change could provide a significant opportunity for plasma FFA reduction. Various factors can impact plasma FFA concentration, such as chronic restriction of dietary energy intake and weight loss, as well as exercise, sleep quality and quantity, and cigarette smoking. In this review, consideration is given to multiple factors which lead to plasma FFA elevation and subsequent disruption of metabolic health. From considering a variety of medical conditions and lifestyle factors, it becomes clear that plasma FFA concentration is a modifiable risk factor for metabolic disease. |
format | Online Article Text |
id | pubmed-8402049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84020492021-08-29 Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease Henderson, Gregory C. Nutrients Review Plasma free fatty acid (FFA) concentration is elevated in obesity, insulin resistance (IR), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), and related comorbidities such as cardiovascular disease (CVD). Furthermore, experimentally manipulating plasma FFA in the laboratory setting modulates metabolic markers of these disease processes. In this article, evidence is presented indicating that plasma FFA is a disease risk factor. Elevations of plasma FFA can promote ectopic lipid deposition, IR, as well as vascular and cardiac dysfunction. Typically, elevated plasma FFA results from accelerated adipose tissue lipolysis, caused by a high adipose tissue mass, adrenal hormones, or other physiological stressors. Reducing an individual’s postabsorptive and postprandial plasma FFA concentration is expected to improve health. Lifestyle change could provide a significant opportunity for plasma FFA reduction. Various factors can impact plasma FFA concentration, such as chronic restriction of dietary energy intake and weight loss, as well as exercise, sleep quality and quantity, and cigarette smoking. In this review, consideration is given to multiple factors which lead to plasma FFA elevation and subsequent disruption of metabolic health. From considering a variety of medical conditions and lifestyle factors, it becomes clear that plasma FFA concentration is a modifiable risk factor for metabolic disease. MDPI 2021-07-28 /pmc/articles/PMC8402049/ /pubmed/34444750 http://dx.doi.org/10.3390/nu13082590 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Henderson, Gregory C. Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease |
title | Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease |
title_full | Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease |
title_fullStr | Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease |
title_full_unstemmed | Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease |
title_short | Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease |
title_sort | plasma free fatty acid concentration as a modifiable risk factor for metabolic disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402049/ https://www.ncbi.nlm.nih.gov/pubmed/34444750 http://dx.doi.org/10.3390/nu13082590 |
work_keys_str_mv | AT hendersongregoryc plasmafreefattyacidconcentrationasamodifiableriskfactorformetabolicdisease |